Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

443
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
443
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Neural Regulation01:37

Neural Regulation

42.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

682
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
682

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current Clinical Trials to Treat Anxiety Disorders in the Elderly: A Registry-Based Review.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Sex differences in the strategies of haptic object memory in early adulthood.

Biology of sex differences·2026
Same author

Different meanings of a three-point decline in MMSE score in Alzheimer's disease and depressive disorder.

BJPsych open·2024
Same author

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers.

Biomedicines·2024
Same author

Clock Drawing Test: Types of Errors and Accuracy in Early Cognitive Screening.

Journal of Alzheimer's disease : JAD·2023
Same author

Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting.

PloS one·2022

Related Experiment Video

Updated: Dec 21, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K

[Dementia with Lewy bodies].

Matthias W Riepe

    Fortschritte Der Neurologie-Psychiatrie
    |May 19, 2020
    PubMed
    Summary

    Diagnosing Lewy body dementia (LBD) using clinical criteria is possible, but it doesn't rule out other causes. Mixed dementia, combining LBD with conditions like Alzheimer's, is common in practice.

    Area of Science:

    • Neurology
    • Neuroscience
    • Geriatrics

    Background:

    • Dementia syndromes frequently present with parkinsonoid extrapyramidal motor symptoms.
    • Established consensus criteria exist for diagnosing Lewy body dementia (LBD).
    • Clinical diagnosis of LBD does not exclude dementia of other etiologies.

    Purpose of the Study:

    • To highlight the diagnostic challenges in differentiating pure Lewy body dementia from mixed dementia syndromes.
    • To emphasize the frequent co-occurrence of Lewy body dementia with other neurodegenerative diseases in clinical settings.

    Main Methods:

    • Review of established consensus criteria for Lewy body dementia diagnosis.
    • Analysis of clinical observations regarding the frequency of mixed dementia forms.

    More Related Videos

    Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
    10:03

    Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

    Published on: August 16, 2020

    11.1K
    Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors
    05:18

    Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors

    Published on: January 21, 2017

    8.5K

    Related Experiment Videos

    Last Updated: Dec 21, 2025

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    18.0K
    Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
    10:03

    Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

    Published on: August 16, 2020

    11.1K
    Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors
    05:18

    Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors

    Published on: January 21, 2017

    8.5K

    Main Results:

    • Clinical diagnosis based on current criteria for Lewy body dementia can be established.
    • The presence of Lewy body dementia does not preclude the existence of other dementia etiologies.
    • Mixed dementia forms, particularly those involving Alzheimer's disease or vascular encephalopathy alongside LBD, are frequently encountered in clinical practice.

    Conclusions:

    • While clinical criteria aid in diagnosing Lewy body dementia, they do not exclude co-existing pathologies.
    • Recognition of mixed dementia is crucial for accurate diagnosis and management, given its high prevalence.
    • Further research is needed to refine diagnostic approaches for complex dementia presentations.